2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors

Details 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors

2007-12-17

2009-12-15

Aulakh, Charanjit S (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S287000

Reexamination Certificate

active

07632844

ABSTRACT:
The compounds of formula Iin which R1, R2, R3, R31, R4, R5, R6 and R7 have the meanings as indicated in the description, are novel effective PDE4 inhibitors.

REFERENCES:
patent: 6121279 (2000-09-01), Gutterer
patent: 6127378 (2000-10-01), Gutterer
patent: 6191138 (2001-02-01), Gutterer
patent: 6410551 (2002-06-01), Gutterer
patent: 7329676 (2008-02-01), Kautz et al.
patent: 2005/0239818 (2005-10-01), Kautz
patent: 2007/0167482 (2007-07-01), Kautz
patent: 2007/0185149 (2007-08-01), Kautz
patent: 2007/0191413 (2007-08-01), Kautz
patent: 2007/0191414 (2007-08-01), Kautz
patent: 2007/0259909 (2007-11-01), Kautz
patent: 0490823 (1992-06-01), None
patent: 9728131 (1997-08-01), None
patent: 9735854 (1997-10-01), None
patent: 9905111 (1999-02-01), None
patent: 9905112 (1999-02-01), None
patent: 9905113 (1999-02-01), None
patent: 9957118 (1999-11-01), None
patent: 0042018 (2000-07-01), None
patent: 0042020 (2000-07-01), None
patent: 0205616 (2002-01-01), None
patent: 0206238 (2002-01-01), None
patent: 2004019945 (2004-03-01), None
Souness et al., “Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors,” Immunopharmacology, vol. 47, pp. 127-162 (2000).
Montana et al., “Chapter 5. Phosphodiesterase 4 Inhibitors,” Annual Reports in Medicinal Chemistry, vol. 36, pp. 47-56 (2001).
Schmidt et al., “The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis,” J. Allergy Clin. Immunol., vol. 108, No. 4, pp. 530-536 (2001).
Dyke et al., “Update on the therapeutic potential of PDE4 inhibitors,” Expert Opin. Investig. Drugs, vol. 11, No. 1, pp. 1-13 (2002).
“Highly Selective Phosphodiesterase 4 Inhibitors for the Treatment of Allergic Skin Diseases and Psoriasis”, Baumer et al.,Inflammation and Allergy—Drug Targets,vol. 6, pp. 17-26 (2006).

Affiliated with

Also associated with

Rating

2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4132018